INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

NRXPNRX Pharmaceuticals, Inc.

CIK 0001719406

EDGAR filingsOpen in network
Disclosed transactions2
Buys / sells0 / 0
Max Insider Score24
Connections4with evidence

NRXP · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
24
AS
Abrams Michael SChief Financial Officer
NRXPNRX Pharmaceuticals, Inc.
Grant or award
A—
75.0K sh
Jul 28, 2026Nov 4, 2026
traded Jul 28, 2026
+99dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Abrams Michael SChief Financial Officer · Nov 4, 2026
  • ← Insider ofevidence
    Javitt Jonathan CDirector, CEO and Chairman · Nov 4, 2026
  • ← Lobbied forevidence
    CONTINENTAL STRATEGY, LLCLDA Q1 2026 first quarter · Pharmacy · Aug 26, 2026
24
JC
Javitt Jonathan CDirector, CEO and Chairman
NRXPNRX Pharmaceuticals, Inc.
Grant or award
A
—
150.0K sh
Jul 28, 2026
Nov 4, 2026
traded Jul 28, 2026
+99d
SEC FORM 4

Evidence

Lobbying

$150K reported · de-duplicated
2026 Q2 $75K via firms2026 Q1 $75K via firms
  • CONTINENTAL STRATEGY, LLC$75K2026 Q2 · posted Aug 26, 2026 · Pharmacy
  • CONTINENTAL STRATEGY, LLC$75K2026 Q1 · posted Aug 26, 2026 · Pharmacy

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.